Preliminary investigation on the abnormal mechanism of CD4+FOXP3+CD25high regulatory T cells in pediatric B‑cell acute lymphoblastic leukemia

Liu,Si‑Xi; Xiao,Hai‑Rong; Wang,Guo‑Bing; Chen,Xiao‑Wen; Li,Chang‑Gang; Mai,Hui‑Rong; Yuan,Xiu‑Li; Liu,Guo‑Sheng; Wen,Fei‑Qiu

doi:10.3892/etm.2018.6326

Preliminary investigation on the abnormal mechanism of CD4+FOXP3+CD25high regulatory T cells in pediatric B‑cell acute lymphoblastic leukemia

Authors:
- Si‑Xi Liu
- Hai‑Rong Xiao
- Guo‑Bing Wang
- Xiao‑Wen Chen
- Chang‑Gang Li
- Hui‑Rong Mai
- Xiu‑Li Yuan
- Guo‑Sheng Liu
- Fei‑Qiu Wen
View Affiliations

Affiliations: Department of Pediatrics, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510630, P.R. China, Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, Guangdong 518036, P.R. China
Published online on: June 19, 2018 https://doi.org/10.3892/etm.2018.6326
Pages: 1433-1441

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study aimed to investigate the changes and regulatory mechanism of cluster of differentiation (CD)4+CD25high forkhead box protein 3 (Foxp3+) regulatory T cells (Tregs) in childhood B‑cell acute lymphocytic leukemia (B‑ALL). A total of 18 children with B‑ALL and 15 age‑matched healthy children were included. Reverse‑transcription quantitative polymerase chain reaction was used to evaluate the mRNA levels of Foxp3, cytotoxic T‑lymphocyte associated protein 4 (CTLA4), glucocorticoid‑induced tumor necrosis factor receptor (GITR), lymphocyte activation gene 3 (LAG3), interleukin (IL)‑2 receptor (R)β/γ, IL‑6Rα/β, mothers against decapentaplegic homolog (Smad)3/4 and runt‑related transcription factor (RUNX)1/3 in CD4‑positive cells. The concentration of cytokines in plasma were measured using a cytometric bead array. Additionally, the proportion of CD4+CD25highFoxp3+ Tregs and levels of associated proteins was analyzed using flow cytometry. The results demonstrated that the proportion of CD4+CD25highFoxp3+ and expression of Foxp3 in children with B‑ALL was significantly higher compared with healthy controls (P<0.05) and that transcription levels of CTLA4, GITR and LAG3 were also significantly elevated (P<0.05). Compared with healthy controls, the expression of IL‑2Rα/β and its downstream molecule phosphorylated signal transducer and activator of transcription 5 (pSTAT5) in CD4‑positive cells significantly increased (P<0.05); however, no significant difference of IL‑2Rγ levels was identified between the two groups. Correlation analysis demonstrated a significant positive correlation between the expression of phosphorylated (p) signal transducer and activator of transcription factor (STAT)5 and CD4+CD25highFoxp3+ Tregs in children with B‑ALL (r=0.17; P<0.05). The plasma concentration of TGF‑β, the expression of its receptor TGF‑βRI/II and downstream molecules Smad3/4 were significantly upregulated in children with B‑ALL (P<0.05), whereas the expression of RUNX1/3 was lower compared with healthy controls (P<0.05). Furthermore, the expression of Smad3 and RUNX1 was positively correlated with CD4+CD25highFoxp3+ Tregs in children with B‑ALL (r=0.87 and 0.60, respectively; P<0.05). Additionally, the expression of pSTAT3 in CD4‑positive cells decreased significantly in pediatric patients with B‑ALL when compared with healthy controls; however, plasma concentrations of IL‑6 was significantly higher (P<0.05). Furthermore, a negative correlation was identified between pSTAT3 and CD4+CD25highFoxp3+ Tregs in pediatric patients with B‑ALL (r=‑0.39; P<0.05). However, no significant differences in IL‑6Rα/β expression were identified between the two groups. The results demonstrated that the excessive activation of IL‑2/pSTAT5 and TGF‑β/Smad signaling, and insufficiency of pSTAT3 may be correlated with increased CD4+CD25highFoxp3+ Tregs in pediatric B‑ALL.

View Figures

View References

1	Onciu M: Acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 23:655–674. 2009. View Article : Google Scholar : PubMed/NCBI
2	Woo JS, Alberti MO and Tirado CA: Childhood B-acute lymphoblastic leukemia: A genetic update. Exp Hematol Oncol. 3:162014. View Article : Google Scholar : PubMed/NCBI
3	Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM, McCubrey JA and Martelli AM: Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. Biochim Biophys Acta. 1863:449–463. 2016. View Article : Google Scholar : PubMed/NCBI
4	Pui CH, Carroll WL, Meshinchi S and Arceci RJ: Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol. 29:551–565. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hangai M, Watanabe K, Shiozawa R, Hiwatari M, Ida K and Takita J: Relapsed acute lymphoblastic leukemia with unusual multiple bone invasions: A case report. Oncol Lett. 7:991–993. 2014. View Article : Google Scholar : PubMed/NCBI
6	Colombo MP and Piconese S: Regulatory-T-cell inhibition versus depletion: The right choice in cancer immunotherapy. Nat Rev Cancer. 7:880–887. 2007. View Article : Google Scholar : PubMed/NCBI
7	Oleinika K, Nibbs RJ, Graham GJ and Fraser AR: Suppression, subversion and escape: The role of regulatory T cells in cancer progression. Clin Exp Immunol. 171:36–45. 2013. View Article : Google Scholar : PubMed/NCBI
8	Facciabene A, Motz GT and Coukos G: T-regulatory cells: Key players in tumor immune escape and angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhu J, Yamane H and Paul WE: Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 28:445–489. 2010. View Article : Google Scholar : PubMed/NCBI
10	Rudensky AY: Regulatory T cells and Foxp3. Immunol Rev. 241:260–268. 2011. View Article : Google Scholar : PubMed/NCBI
11	Shevach EM: Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 30:636–645. 2009. View Article : Google Scholar : PubMed/NCBI
12	Peters JM and Ansari MQ: Multiparameter flow cytometry in the diagnosis and management of acute leukemia. Arch Pathol Lab Med. 135:44–54. 2011.PubMed/NCBI
13	Subspecialty Group of Hematology Diseases; The Society of Pediatrics; Chinese Medical Association; Editorial Board; Chinese Journal of Pediatrics. Recommendations for diagnosis and treatment of acute lymphoblastic leukemia in childhood (3rd revised version). Zhonghua Er Ke Za Zhi. 44:392–395. 2006.(In Chinese). PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Yamamoto T, Yanagimoto H, Satoi S, Toyokawa H, Hirooka S, Yamaki S, Yui R, Yamao J, Kim S and Kwon AH: Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas. 41:409–415. 2012. View Article : Google Scholar : PubMed/NCBI
16	Beyer M, Classen S, Endl E, Kochanek M, Weihrauch MR, Debey-Pascher S, Knolle PA and Schultze JL: Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3. Clin Dev Immunol. 2011:7340362011. View Article : Google Scholar : PubMed/NCBI
17	Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z and Xi X: Elevated frequencies of CD4⁺ CD25⁺ CD1271o regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 129:1373–1381. 2011. View Article : Google Scholar : PubMed/NCBI
18	Weiss L, Melchardt T, Egle A, Grabmer C, Greil R and Tinhofer I: Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer. 117:2163–2169. 2011. View Article : Google Scholar : PubMed/NCBI
19	Li AH, Qiu GQ, Gu WY, Ling Y, Weng KZ, Tan Q and Cao XS: Expression of CD4+ CD25+ regulatory T cells in the patients with acute lymphocytic leukemia. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 23:439–442. 2007.(In Chinese). PubMed/NCBI
20	Wu CP, Qing X, Wu CY, Zhu H and Zhou HY: Immunophenotype and increased presence of CD4(+)CD25(+) regulatory T cells in patients with acute lymphoblastic leukemia. Oncol Lett. 3:421–424. 2012. View Article : Google Scholar : PubMed/NCBI
21	Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE and Bromberg JS: Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 182:259–273. 2009. View Article : Google Scholar : PubMed/NCBI
22	Cheng G, Yu A, Dee MJ and Malek TR: IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development. J Immunol. 190:1567–1575. 2013. View Article : Google Scholar : PubMed/NCBI
23	Rouse M, Nagarkatti M and Nagarkatti PS: The role of IL-2 in the activation and expansion of regulatory T-cells and the development of experimental autoimmune encephalomyelitis. Immunobilogy. 218:674–682. 2013. View Article : Google Scholar
24	Schlenner SM, Weigmann B, Ruan Q, Chen Y and von Boehmer H: Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut. J Exp Med. 209:1529–1535. 2012. View Article : Google Scholar : PubMed/NCBI
25	Rahimi RA and Leof EB: TGF-beta signaling: A tale of two responses. J Cell Biochem. 102:593–608. 2007. View Article : Google Scholar : PubMed/NCBI
26	Klunker S, Chong MM, Mantel PY, Palomares O, Bassin C, Ziegler M, Rückert B, Meiler F, Akdis M, Littman DR and Akdis CA: Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J Exp Med. 206:2701–2715. 2009. View Article : Google Scholar : PubMed/NCBI
27	Liao W, Lin JX and Leonard WJ: Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 38:13–25. 2013. View Article : Google Scholar : PubMed/NCBI
28	Chen Q, Kim YC, Laurence A, Punkosdy GA and Shevach EM: IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo. J Immunol. 186:6329–6337. 2011. View Article : Google Scholar : PubMed/NCBI
29	Mahmud SA, Manlove LS and Farrar MA: Interleukin-2 and STAT5 in regulatory T cell development and function. JAKSTAT. 2:e231542013.PubMed/NCBI
30	Classen S, Zander T, Eggle D, Chemnitz JM, Brors B, Büchmann I, Popov A, Beyer M, Eils R, Debey S and Schultze JL: Human resting CD4+ T cells are constitutively inhibited by TGF beta under steady-state conditions. J Immunol. 178:6931–6940. 2007. View Article : Google Scholar : PubMed/NCBI
31	Delisle JS, Giroux M, Boucher G, Landry JR, Hardy MP, Lemieux S, Jones RG, Wilhelm BT and Perreault C: The TGF-β-Smad3 pathway inhibits CD28-dependent cell growth and proliferation of CD4 T cells. Genes Immun. 14:115–126. 2013. View Article : Google Scholar : PubMed/NCBI
32	Seoane J and Gomis RR: TGF-β family signaling in tumor suppression and cancer progression. Cold Spring Harb Perspect Biol. 9:a0222772017. View Article : Google Scholar : PubMed/NCBI
33	Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C and Grippo PJ: TGF-β: Duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 106:djt3692014. View Article : Google Scholar : PubMed/NCBI
34	Bruno L, Mazzarella L, Hoogenkamp M, Hertweck A, Cobb BS, Sauer S, Hadjur S, Leleu M, Naoe Y, Telfer JC, et al: Runx proteins regulate Foxp3 expression. J Exp Med. 206:2329–2337. 2009. View Article : Google Scholar : PubMed/NCBI
35	Neurath MF and Finotto S: IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 22:83–89. 2011. View Article : Google Scholar : PubMed/NCBI
36	Sun Q, Liu Q, Zheng Y and Cao X: Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol Immunol. 45:2929–2936. 2008. View Article : Google Scholar : PubMed/NCBI